Novel mch receptor antagonists

A compound of formula I:

• or a pharmaceutically acceptable salt, solvate, enantiomer, mixture of diastereomers, or prodrug thereof;
• wherein
• Ar1 is a cyclic group optionally substituted with one to five groups selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, C1-C8 alkoxy, C1-C8 alkylaryl, phenyl, aryl, C3-C8 cycloalkyl, C1-C8 alkylcycloalkyl, cyano, —(CH2)nNR1R2, C1-C8 haloalkyl, halo, (CH2)nCOR6, (CH2)nNR5SO2R6, —(CH2)nC(O)NR1R2, and C1-C8 alkylheterocyclic;
• wherein the alkyl, alkenyl, cycloalkyl, phenyl, and aryl are each optionally substituted with one to three groups selected from hydroxy, C1-C8 alkoxyalkyl, C1-C8 alkyl, halo, C1-C8 haloalkyl, nitro, cyano, amino, carboxamido, and oxo;
• L1 is a bond or a linker having a main chain of 1 to 14 atoms or represented by the formula X2—(CR3R4)m—X3 wherein R3 and R4 are independently hydrogen, C1-C8 alkyl, C2-C8 alkylene, C2-C8 alkynyl, phenyl, aryl, C1-C8 alkylaryl, (CH2)nNR5SO2R6, (CH2)nC(O)R6, (CH2)nCONR1R2 or (CH2)nC(O)OR6;
• wherein the alkyl, alkenyl, phenyl, and aryl groups are optionally substituted with one to five substitutents independently selected from oxo, nitro, cyano, C1-C8 alkyl, aryl, halo, hydroxy, C1-C8 alkoxy, C1-C8 halaoalkyl, (CH2)nC(O)R6, (CH2)nCONR1R2 and (CH2)nC(O)OR6;
• X2 is independently —O, —CH, —CHR6, —NR5, S, SO, or SO2;
• X3 is independently —O, —CH, —CHR6, —NR5, S, SO, or SO2;
• Ar2 is a 6-member monocyclic carbocyclic or heterocyclic group or positional isomer thereof, having 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur;
• and optionally substituted with one to three substitutents selected from C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, hydroxy, C1-C8 alkoxy, C1-C8 alkylaryl, phenyl, aryl, C3-C8 cycloalkyl, C1-C8 alkylcycloalkyl, cyano, C1-C8 haloalkyl, halo, (CH2)nC(O)R6, (CH2)nC(O)OR6, (CH2)nNR5SO2R6, (CH2)nC(O)NR1R2, and C1-C8 alkylheterocyclic;
• provided that the result of the substitution is a stable fragment or group;
• Ar3 is a 6-member monocyclic aromatic or nonaromatic, carbocyclic or heterocyclic ring having 0, 1, 2, or 3 heteroatoms selected from nitrogen, oxygen and sulfur and optionally substituted with one to three substitutents independently selected from halo, —NHR5, C1-C8 haloalkyl, C3-C8 cycloalkyl, C1-C8 alkyl, hydroxy, alkoxy, (CH2)nC(O)R6, (CH2)nC(O)OR6, (CH2)nNR5SO2R6, (CH2)nC(O)NR1R2, phenyl, C1-C8 alkylaryl, and aryl;
• provided that Ar2 and Ar3 or positional isomn ersz thereof are linked by a bond;
• L2 is a bond or a divalent linker having a chain length of between 1 and 14 atoms in the main chain or represented by the formula:
• X4—(CR3R4)m—X5 wherein R3 and R4 are independently hydrogen, C1-C8 alkyl, C2-C8 alkylene, C2-C8 alkynyl, phenyl, aryl, C1-C8 alkylaryl, (CH2)nNR5SO2R6, (CH2)nC(O)R6, (CH2)nCONR1R2 or (CH2)nC(O)OR6;
• wherein the alkyl, alkenyl, phenyl, and aryl groups are optionally substituted with one to five substitutents independently selected from oxo, nitro, cyano, C1-C8 alkyl, aryl, halo, hydroxy, C1-C8 alkoxy, C1-C8 halaoalkyl, (CH2)nC(O)R6, (CH2)nCONR1R2 and (CH2)nC(O)OR6;
• wherein X4 is selected from the group consisting of —CH, CHR6, —O, —NR5, —NC(O)—, —NC(S), —C(O)NR5—, —NR6C(O)NR6, —NR6C(S)NR6, —NRSO2R7, and —NR6C(NR5) NR6;
• X5 is selected from the group consisting of —CH2, —CH, —OCH2CH2, —SO, —SO2, —S, and —SCH2;
• wherein the group X4—(CR3R4)m—X5 imparts stability to the compound of formula (1) and may be a saturated or unsaturated chain or linker;
• Q is a basic group or a group represented by —NR1R2 ;
• wherein
• R1 and R2 are independently selected from hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkane, C1-C8 alkylaryl, —C(O)C1-C8 alkyl, —C(O)OC1-C8 alkyl, C1-C8 alkylcycloalkane, (CH2)nC(O)OR5, (CH2)nC(O)R5, (CH2)nC(O)NR1R2, and (CH2)nNSO2R5;
• wherein each of the alkyl, alkenyl, aryl are each optionally substituted with one to five groups independently selected from C1-C8 alkyl, C2-C8 alkenyl, phenyl, and alkylaryl;
• and wherein R1 and R2 may combine together, and with the nitrogen atom to which they are attached or with 0, 1, or 2 atoms adjacent to the nitrogen atom to form a nitrogen containing heterocycle which may have substituents;
• R5 is hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C5-C8 alkylaryl, (CH2)nNSO2C1-C8 alkyl, (CH2)nNSO2phenyl, (CH2)nNSO2aryl, —C(O)C1-C8 alkyl, or —C(O)OC1-C8 alkyl;
• and
• R6 is a group independently selected from hydrogen, C1-C8 alkyl, phenyl, aryl, C1-C8 alkylaryl, and C3-C8 cycloalkyl;
• wherein m is an integer from 0 to 4;
• and n is an integer from 0 to 3.